Neuropatía por disulfiram: Comunicación de tres casos clínicos

dc.creatorBevilacqua,Jorge A
dc.creatorDíaz S,Mario
dc.creatorDíaz T,Violeta
dc.creatorSilva R,Carlos
dc.creatorFruns Q.,Manuel
dc.date2002-09-01
dc.date.accessioned2017-03-07T15:33:31Z
dc.date.available2017-03-07T15:33:31Z
dc.identifierhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872002000900012
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/387149
dc.descriptionDisulfiram is widely used for aversive treatment of alcoholism. Although it is well tolerated in most patients, one in 15,000 patients will develop peripheral neuropathy every year, which is frequently misdiagnosed as alcoholic neuropathy. Disulfiram neuropathy can be mild or severe, depending on diverse factors such as time of exposure and the dosage. Most patients will present with a motor-sensory neuropathy of the lower limbs, which tends to improve as disulfiram administration ceases, however some cases may remain with permanent sequelae. We report the clinical, laboratory and electrophysiological features of three patients who developed disulfiram neuropathy during treatment of alcoholism. Recovery was incomplete at 8 weeks after treatment cessation in all of them. No other findings justified the clinical features described in these patients. Considering the incidence of alcoholism and the wide use of disulfiram treatment in Chile, we suggest that disulfiram neuropathy is being underdiagnosed. We also stress the fact that disulfiram neuropathy could be avoided by using lower doses (Rev Méd Chile 2002; 130: 1037-42).
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.sourceRevista médica de Chile v.130 n.9 2002
dc.subjectAlcohol related disorders
dc.subjectDisulfiram
dc.subjectDrug toxicity
dc.subjectNeuropathies
dc.titleNeuropatía por disulfiram: Comunicación de tres casos clínicos
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución